Chronic Lymphocytic Leukemia

>

Latest News

Superior Outcomes Seen With Fixed-Duration Ibrutinib/Venetoclax in CLL
Superior Outcomes Seen With Fixed-Duration Ibrutinib/Venetoclax in CLL

September 21st 2023

In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.

Pirtobrutinib Shows Strong Efficacy in Recurrent CLL/SLL After BTK Inhibition
Pirtobrutinib Shows Strong Efficacy in Recurrent CLL/SLL After BTK Inhibition

September 15th 2023

CLL Investigators Look to Write the Next Chapter of BCL-2 Inhibition
CLL Investigators Look to Write the Next Chapter of BCL-2 Inhibition

September 8th 2023

Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?
Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?

September 7th 2023

Ofatumumab-Based Regimens Improve Survival in CLL
Ofatumumab-Based Regimens Improve Survival in CLL

August 28th 2023

Video Series
Video Interviews
Podcasts

More News